From First to Second-Line: The New Frontier in Colorectal Cancer Treatment
This study explores the efficacy of second-line treatment with ramucirumab and FOLFIRI in patients with RAS wild-type metastatic colorectal cancer, revealing promising results for this treatment regimen.